TY - JOUR
T1 - Forty-year survival with the starr-edwards heart valve prosthesis
AU - Gao, Guangqiang
AU - Wu, Ying Xing
AU - Grunkemeier, Gary L.
AU - Furnary, Anthony P.
AU - Starr, Albert
N1 - Copyright:
Copyright 2021 Elsevier B.V., All rights reserved.
PY - 2004/1
Y1 - 2004/1
N2 - Background and aim of the study: The study aim was to update an analysis of the long-term survival of heart valve replacement using the Starr-Edwards prosthesis. Methods: Cases of isolated aortic (AVR, n = 2,247) and mitral (MVR, n = 1,406) valve replacement with Starr-Edwards prostheses implanted between 1960 and 1997, with follow up to 2003, were reviewed. Introduced in 1965, the Models A1200/1260, M6120 are still in use (Current), while other models have been discontinued (Discontinued). For AVR, 938 valves were Discontinued, with a total follow up of 8,506 patient-years (pt-yr) and a maximum of 41 years; by comparison, 1,309 valves were Current, with a total follow up of 11,586 pt-yr and a maximum of 36.1 years. For MVR, 635 valves were Discontinued, with a total follow up of 6,454 pt-yr and maximum of 37.2 years; and 771 valves were Current, with a total follow up of 6,211 pt-yr and maximum of 37.0 years. Results: Kaplan-Meier (KM) survival at 10 years was 53% for AVR and 51% for MVR; KM survival at 20 years was 23% for both AVR and MVR; KM survival at 30 years was 8% for both AVR and MVR; KM sur-vival at 40 years was 4% for AVR. The standard error for all KM percentages was 1%. Four patients are cur-rently alive with their original valves, more than 40 years after implantation. Conclusion: This series of patients, who underwent valve replacement with the Starr-Edwards valve, now have a follow up extending beyond 40 years, thereby confirming the excellent durability of this valve.
AB - Background and aim of the study: The study aim was to update an analysis of the long-term survival of heart valve replacement using the Starr-Edwards prosthesis. Methods: Cases of isolated aortic (AVR, n = 2,247) and mitral (MVR, n = 1,406) valve replacement with Starr-Edwards prostheses implanted between 1960 and 1997, with follow up to 2003, were reviewed. Introduced in 1965, the Models A1200/1260, M6120 are still in use (Current), while other models have been discontinued (Discontinued). For AVR, 938 valves were Discontinued, with a total follow up of 8,506 patient-years (pt-yr) and a maximum of 41 years; by comparison, 1,309 valves were Current, with a total follow up of 11,586 pt-yr and a maximum of 36.1 years. For MVR, 635 valves were Discontinued, with a total follow up of 6,454 pt-yr and maximum of 37.2 years; and 771 valves were Current, with a total follow up of 6,211 pt-yr and maximum of 37.0 years. Results: Kaplan-Meier (KM) survival at 10 years was 53% for AVR and 51% for MVR; KM survival at 20 years was 23% for both AVR and MVR; KM survival at 30 years was 8% for both AVR and MVR; KM sur-vival at 40 years was 4% for AVR. The standard error for all KM percentages was 1%. Four patients are cur-rently alive with their original valves, more than 40 years after implantation. Conclusion: This series of patients, who underwent valve replacement with the Starr-Edwards valve, now have a follow up extending beyond 40 years, thereby confirming the excellent durability of this valve.
UR - http://www.scopus.com/inward/record.url?scp=4344596945&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=4344596945&partnerID=8YFLogxK
M3 - Article
C2 - 14765846
AN - SCOPUS:4344596945
SN - 0966-8519
VL - 13
SP - 91
EP - 96
JO - The Journal of heart valve disease
JF - The Journal of heart valve disease
IS - 1
ER -